Dr Lalchandani Labs Share Price Today | Stock Price & Dr Lalchandani Labs Share Screener
Track the current Dr Lalchandani Labs share price and stock price live with TickJournal's free stock screener. Track DLCL market value to gauge the company's total market size. Use the Dr Lalchandani Labs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Dr Lalchandani Labs opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Dr Lalchandani Labs Share Price Chart
Track the current stock price of Dr Lalchandani Labs with an interactive chart. Analyse DLCL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Dr Lalchandani Labs stock quote in one place.
Dr Lalchandani Labs Company Profile - Fundamental Screener
Screen Dr Lalchandani Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for DLCL shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Healthcare Services industry, and it trades under ISIN INE871Z01013.
Company Details
Classification
Identifiers and Leadership
Dr Lalchandani Labs Balance Sheet Screener
Screen DLCL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹18, up from ₹16 in 2025.
Latest statistics put total assets at ₹18 and shareholder funds at ₹14, with a leverage ratio of 0.39.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
Assets |
|||||||||
| Total Assets | 18 | 16 | 15 | 18 | 18 | 15 | 12 | 10 | 6 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 3 | 4 | 4 | 5 | 6 | 5 | 4 | 3 | 2 |
Liabilities |
|||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 4 | 3 | 3 | 2 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||||||
| Total Equity | 14 | 10 | 10 | 9 | 11 | 10 | 9 | 8 | 3 |
| Share Capital | 9 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
| Reserves & Surplus | 6 | 6 | 5 | 5 | 6 | 5 | 4 | 4 | 0 |
Dr Lalchandani Labs Income Statement Screener - Profit & Revenue Analysis
Screen Dr Lalchandani Labs income statement and profit fundamentals. Analyze DLCL quarterly results. Dr Lalchandani Labs reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹0 and net profit was ₹0.
In that period expenses were ₹0, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹4 and net profit of ₹0.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||||
| Revenue | 0 | 4 | 5 | 5 | 5 | 11 | 10 | 6 | 5 | 3 |
| Expenses | 0 | 4 | 4 | 5 | 5 | 9 | 8 | 5 | 4 | 2 |
Operating Costs and Margins | ||||||||||
| EBITDA | 0 | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 |
| Operating Profit % | 0.00% | 16.00% | 21.00% | 4.00% | 2.00% | 21.00% | 23.00% | 21.00% | 23.00% | 22.00% |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
Profit and Earnings | ||||||||||
| Profit Before Tax | 0 | 0 | 0 | 1 | -2 | 1 | 1 | 1 | 1 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 1 | -2 | 1 | 1 | 1 | 1 | 0 |
| EPS | 0.00 | 0.07 | 0.96 | 1.43 | -3.61 | 2.15 | 2.33 | 1.09 | 1.23 | 0.89 |
Dr Lalchandani Labs Cash Flow Screener - Liquidity Fundamentals
Screen DLCL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹0, and net cash flow was an inflow of ₹1.
Over the same period, investing activities provided ₹0 and financing activities provided ₹1.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||
| Operating Activities | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 1 |
| Investing Activities | 0 | 1 | 0 | -2 | -2 | -1 | -2 | -1 |
Financing and Net Cash | ||||||||
| Financing Activities | 1 | -2 | 0 | 0 | 2 | 1 | 4 | 2 |
| Net Cash Flow | 1 | -1 | 0 | 1 | 1 | 0 | 1 | 1 |
Dr Lalchandani Labs Shareholding Pattern Screener
See Dr Lalchandani Labs shareholding pattern with promoter, FII, and DII holdings. Check Dr Lalchandani Labs promoter holding and ownership changes for DLCL on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 32.90%, foreign institutions 0.00%, domestic institutions 0.00% and the public 62.74%, spread across 234 shareholders.
The shareholder count was 234 in 2026-Mar, compared with 246 in 2025-Mar.
| Item | 2026-Mar | 2025-Mar | 2025-Sept | 2024-Mar | 2024-Sept | 2023-Mar | 2023-Sept | 2022-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 32.90% | 48.32% | 31.15% | 60.78% | 57.18% | 60.78% | 60.78% | 60.78% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 62.74% | 45.68% | 64.51% | 32.94% | 36.54% | 32.75% | 33.03% | 33.58% |
| Other Holding | 4.35% | 6.00% | 4.34% | 6.28% | 6.28% | 6.46% | 6.18% | 5.63% |
| Shareholder Count | 234 | 246 | 206 | 165 | 181 | 162 | 159 | 151 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Dr Lalchandani Labs. Dr Lalchandani Labs dividend yield can be compared with peers and other stocks in the market.
Dr Lalchandani Labs Stock Index Membership - Nifty & Sensex
See which indices include Dr Lalchandani Labs stock. Check DLCL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Dr Lalchandani Labs Market Events Screener - Corporate Actions
Get Dr Lalchandani Labs corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Dr Lalchandani Labs stock events that may affect DLCL share price, along with derivatives, futures and options activity and sector gainers.
7 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated June 3, 2026, with a record date of June 3, 2026.
It is followed by Rights dated January 27, 2026 and Quarterly Result Announcement dated November 14, 2025.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-06-03 | 2026-06-03 | Quarterly Result Announcement | NA | 6.75% |
| 2026-01-27 | 2026-01-27 | Rights | 1:1 | -11.76% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -5.02% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -12.60% |
| 2025-05-01 | 2025-05-01 | Quarterly Result Announcement | NA | -6.12% |
| 2024-10-14 | 2024-10-14 | Quarterly Result Announcement | NA | 5.14% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | -9.31% |
Dr Lalchandani Labs Competitors Screener - Peer Stocks Comparison
Screen DLCL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Apollo Hospitals | 125,272 | 53.90 | 25,420 | 15.58% | 2,003 | 61.89 |
| Max Healthcare Institute | 100,339 | 71.20 | 8,536 | 18.82% | 1,442 | 76.17 |
| Manipal Health Enterprises | 92,333 | 104.20 | 10,521 | 25.80% | 917 | 60.80 |
| Aster DM Quality Care | 64,325 | 116.10 | 4,769 | 11.25% | 427 | 57.55 |
| Fortis Healthcare | 60,910 | 57.00 | 9,179 | 16.93% | 1,064 | 57.30 |
| Narayana Hrudayalaya | 38,984 | 45.00 | 7,996 | 43.43% | 811 | 61.49 |
| Global Health | 38,830 | 62.80 | 4,509 | 19.56% | 554 | 64.64 |
| Dr. Lal Path Labs | 33,237 | 57.20 | 2,864 | 12.11% | 510 | 54.28 |
| Krishna Institute of Medical Sciences | 32,269 | 163.00 | 3,931 | 28.16% | 242 | 66.73 |
| Syngene International | 17,533 | 95.70 | 3,809 | 2.56% | 317 | 61.78 |
Dr Lalchandani Labs Company Announcements - News & Reports Screener
Screen DLCL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 13, 2026.
The next most recent announcements are dated September 30, 2026 and September 17, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-09-30 | Closure of Trading Window | - |
| 2026-09-17 | Extension For Annual General Meeting For FY 2025-2026 | - |
| 2026-07-17 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-03 | Board Meeting Outcome for Approval Of Audited Financial Statement For Half Year And Year Ended March 31 2026 | - |
| 2026-06-03 | Approval Of Audited Financial Results For The Half Year And Year Ended March 31 2026 | - |
| 2026-05-30 | Announcement under Regulation 30 (LODR)-Meeting Updates | - |
| 2026-05-28 | Opening Of New Centre At Dwarka Delhi | - |
| 2026-05-27 | Board Meeting Intimation for Consideration And Approval Of Financial Results Of The Company For Half Year And Year Ended March 31 2026 | - |
| 2026-05-04 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | - |
| 2026-04-30 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-22 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-04-13 | Reply To The Clarification Sought By BSE | - |
| 2026-04-13 | Clarification sought from Dr Lalchandani Labs Ltd | - |
| 2026-04-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-27 | Closure of Trading Window | - |
| 2026-03-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-03-05 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-03-02 | Approval Of Basis Of Allotment Under Right Issue | - |
| 2026-03-02 | Board Meeting Outcome for Outcome Of Board Meeting Held On Monday March 02 2026 | - |
Frequently Asked Questions
How is the company valued right now?
The P/B ratio is 0.39. Market capitalisation stands at ₹5.50 Cr. The company operates in the Healthcare sector, in the Healthcare Services industry, so compare these ratios with its sector peers in the table above.
About This Data
Key statistics were last updated on November 20, 2026. This page covers 9 balance sheet periods, 10 income statement periods, 8 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.